Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo
Rhea-AI Summary
Aspire Biopharma (NASDAQ:ASBP) subsidiary Buzz Bomb Caffeine Company announced that elite ultramarathoner Ashley Paulson will attempt the female world record for the fastest 100-mile treadmill run at the Boston Marathon Expo on April 18, 2026 at the Hynes Convention Center.
Paulson previously set the 100-mile road world record on February 20, 2026 with a time of 12:19:34 and will aim to beat the treadmill mark of 14:15:08. The event will be live and open to spectators, showcasing Buzz Bomb products.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ASBP
On the day this news was published, ASBP declined 10.10%, reflecting a significant negative market reaction. Argus tracked a trough of -21.5% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $169K from the company's valuation, bringing the market cap to $1.51M at that time. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ASBP was down 44.94% with heavy volume while momentum scanner only flagged peer XCUR moving 3.68% up and no peers with same-direction momentum, pointing to stock-specific pressure rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 16 | Acquisition LOI | Positive | -44.9% | Letter of Intent to acquire Dura Driver Control Systems for $30 million cash. |
| Apr 15 | Retail partnership | Positive | -54.2% | Buzz Bomb signs brokerage deal with Interwest to expand retail distribution. |
| Mar 19 | Distribution agreement | Positive | -6.0% | TruLife Distribution engaged to drive national retail expansion for BUZZ BOMB™. |
| Mar 17 | Leadership hire | Positive | -10.2% | Appointment of veteran John Choe as Western Sales Director for Buzz Bomb. |
| Mar 12 | Product marketing | Positive | -10.0% | Buzz Bomb to feature BUZZ BOMB™ product at The Health & Fitness Show 2026. |
Recent corporate and growth announcements have repeatedly coincided with sharp negative price reactions, suggesting a pattern of selling into news.
Over the last month, Aspire Biopharma announced multiple Buzz Bomb distribution and marketing initiatives plus an LOI to acquire Dura Driver Control Systems for $30 million. Despite seemingly growth-oriented developments, shares fell 44.94% after the LOI, 54.21% on the Interwest partnership, and saw smaller declines on national distribution, a sales director hire, and trade show exposure. Today’s ambassador-focused event fits this marketing-heavy trajectory amid sustained market skepticism.
Market Pulse Summary
The stock dropped -10.1% in the session following this news. A negative reaction despite promotional news fits the recent pattern, where five prior growth and marketing updates coincided with declines up to 54.21%. This ambassador-focused event adds visibility for Buzz Bomb but does not address prior filings highlighting losses, working capital deficits, and financing structures, so traders may have continued to de-emphasize branding headlines in favor of underlying balance sheet concerns.
AI-generated analysis. Not financial advice.
Elite Ultra-Marathoner targets her second World Record in two months following historic
ESTERO, FL / ACCESS Newswire / April 17, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP) ("Aspire" or the "Company") wholly owned subsidiary, Buzz Bomb Caffeine Company, is proud to announce that elite ultra-marathoner and BUZZ BOMB™ Global Brand Ambassador Ashley Paulson will attempt to shatter the female world record for the fastest 100-mile treadmill run.
The historic attempt will take place live at the Boston Marathon Expo at the John B. Hynes Veterans Memorial Convention Center on Saturday, April 18, 2026. This Expo is held in conjunction with the Boston Marathon. Paulson aims to beat the current mark of 14:15:08, pushing the limits of human endurance in front of thousands of spectators during one of the most prestigious weekends in global running.
"Ashley embodies the grit and rapid performance that BUZZ BOMB™ was designed to support," said Kraig Higginson, Interim CEO of Aspire Biopharma. "After her dominant road world record in February, we are thrilled to fuel her next history-making effort in Boston."
Paulson is no stranger to the record books. On February 20, 2026, she set the current world record for the fastest female to run 100 miles (road) at the Jackpot 100 Mile Ultra with a staggering time of 12:19:34. This upcoming challenge transitions her elite speed to the treadmill, a feat requiring immense mental and physical fortitude.
Commenting on her use of BUZZ BOMB™ throughout the 100 Mile Ultra race, Ashley Paulson said, "I was using a BUZZ BOMB™ every hour to keep my energy steady while chasing the 100-mile world record. The easy delivery under the tongue kicks in fast without the upset stomach issues of traditional caffeine. It's just smooth, consistent energy that kept me cruising mile after mile."
Paulson's upcoming attempt will showcase her endurance and the mental fortitude required for long-distance treadmill running. This event highlights the intersection of elite athleticism and specialized performance support during one of the most significant weekends in the running community. Please come and meet Buzz Bomb representatives that will be supporting Ashley at the Expo!
Event Details:
Athlete: Ashley Paulson
Goal: Fastest Female 100-Mile Treadmill Run (Target: < 14:15:08)
Date: Saturday, April 18, 2026
Location: Boston Marathon Expo, Hynes Convention Center, 900 Boylston St, Boston, MA
Ashley Paulson Wins the 2026 USATF 100-Mile Road Championship
For more about Ashley Paulson, follow her on Instagram, TikTok and Facebook.
https://www.instagram.com/ashkickn/?hl=en,
https://www.tiktok.com/@ashkickn1
https://www.facebook.com/ashley.j.paulson/
BUZZ BOMB™ Caffeine Products
Unlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.
BUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.
To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:
BUZZ BOMB™ Variety Pack
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma delivers supplements to the body rapidly and precisely.
For more information, please visit www.aspirebiolabs.com
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire